Antiphospholipid syndrome (APS) is an entity with specific clinical and analytical features independent of other autoimmune entities. The etiopathogenesis of the condition is unknown. This means that the mechanism by which antiphospholipid antibodies cause fetal losses is not known. However, it seems that a coagulation phenomenon (thrombosis) may be at the basis of the problem.
Ultimately, pregnant patients affected by SAP are at risk of recurrent miscarriages and recurrent late fetal losses. Therefore, it is imperative to rule out this syndrome in these patients by determining the possible presence of APL or ACA.
Once other causes of miscarriage have been ruled out, and a diagnosis of SAP has been made, treatment will be based fundamentally on drugs with an antiplatelet (acetylsalicylic acid) and/or anticoagulant (Heparin) effect.